Depixus receives the Ignite Award at SLAS2024 for its MAGNA™ technology

Depixus, a pioneering intereactomics company, has been recognized for their groundbreaking MAGNA™ technology with the prestigious Society for Laboratory Automation and Screening (SLAS) Ignite Award at the society’s annual International Conference and Exhibition in Boston, MA. This award was presented alongside the unveiling of Depixus’ MAGNA One™ instrument at the conference.

The Ignite Award is given to companies that are revolutionizing the life sciences through their innovative technologies. The selection process involved evaluation by a panel of experts on criteria such as excellence in innovation, marketing presence, impact, funding, and balanced leadership. Out of 16 participating companies, Depixus was one of only eight finalists for this prestigious award.

MAGNA One utilizes magnetic force spectroscopy to enable high-throughput analysis of dynamic biomolecular interactions. It is the first technology to offer real-time measurements from thousands of individual molecules simultaneously, making it especially useful for studying challenging targets such as RNA and protein-protein interactions. This technology provides valuable insights into disease mechanisms and accelerates the development of novel therapeutics.

Depixus CEO Gordon Hamilton expressed his excitement about winning the Ignite Award, emphasizing the company’s innovative technology and its potential to impact the understanding and treatment of diseases where new treatments are urgently needed. Chief Commercial Officer Steve Klose added that this timing coincides with Depixus’ technology access program launch and commercial rollout of MAGNA One, marking a significant milestone for the company.

For more information on Depixus and their MAGNA One™ instrument, visit depixus.com or contact Steve Klose at steve.klose@depixus.com .

By Editor

Leave a Reply